ACTON, Mass.– Insulet Corporation (NASDAQ: PODD), maker of the Omnipod® insulin delivery system, has promoted Eric Benjamin to Chief Operating Officer, effective immediately. The company also named Manoj Raghunandanan as Chief Growth Officer.
Benjamin, who joined Insulet in 2015, will oversee strategy, business development, technology, research and development, and a new Growth unit. His expanded role places him in charge of product innovation, market expansion, and commercial execution. Previously, as Executive Vice President and Chief Product & Customer Experience Officer, he led the launch of Omnipod DASH® and Omnipod 5®, expanded into the type 2 diabetes market, and advanced digital engagement.
“Eric has been a driving force in Insulet’s success,” said Ashley McEvoy, President and CEO. “He combines vision, execution, and a mission-first mindset that sets him apart – spotting opportunities in evolving markets, setting bold strategies, and building high-performing teams that deliver results.”
“I’m honored to step into this role at such an important moment for Insulet and exciting time in the advancement of diabetes care,” said Benjamin. “We have an extraordinary opportunity to continue advancing life-changing technology and broaden global access to improve the lives of people with diabetes.”
Raghunandanan, who joins as Chief Growth Officer, previously spent two decades in consumer health leadership at Kenvue (formerly Johnson & Johnson Consumer Health). He most recently served as general manager of Kenvue’s Northern European business and sat on the company’s Executive Committee, overseeing a $6 billion global OTC portfolio. At Insulet, he will lead the newly formed Growth organization, focusing on strategy, demand generation, commercial capabilities, and global brand management.
